TITLE

A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study

AUTHOR(S)
Aquino, V. M.; Harvey, A. R.; Garvin, J. H.; Godder, K. T.; Nieder, M. L.; Adams, R. H.; Jackson, G. B.; Sandler, E. S.
PUB. DATE
October 2005
SOURCE
Bone Marrow Transplantation;Oct2005, Vol. 36 Issue 7, p611
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Summary:Severe mucositis is a common cause of morbidity in hematopoietic stem cell transplant (HSCT) recipients. Glutamine has been shown to reduce mucositis in children receiving chemotherapy. Patients were randomized in a double-blind manner to receive glutamine or glycine at a dose of 2 g/m2/dose (maximum dose 4 g) twice daily until 28 days post transplant or discharge if sooner. Mucositis was graded by use of a modified Walsh scale. A total of 120 children were evaluable: 57 children received glutamine and 63 received glycine. The mean mucositis score was 3.0±0.3 vs 3.9±0.4 (P=0.07) in the glutamine and glycine groups, respectively. The glutamine group demonstrated a reduction in mean number of days of intravenous narcotics use (12.1±1.5 vs 19.3±2.8 in the glycine group, P=0.03) and total parenteral nutrition (17.3±1.7 vs 27.3±3.6 in glycine group, P=0.01). There was no statistically significant difference in toxicity between the two groups. Glutamine appears to be safe and beneficial in reducing the severity of mucositis. Strong consideration should be given to include oral glutamine supplementation as a routine part of supportive care of SCT patients.Bone Marrow Transplantation (2005) 36, 611–616. doi:10.1038/sj.bmt.1705084; published online 8 August 2005
ACCESSION #
18300003

 

Related Articles

  • Encephalopathy in pediatric patients after allogeneic hematopoietic stem cell transplantation is associated with a poor prognosis. Woodard, P.; Helton, K.; McDaniel, H.; Khan, R. B.; Thompson, S.; Hale, G.; Benaim, E.; Kasow, K.; Leung, W.; Horwitz, E.; Srivastava, D. K.; Tong, X.; Yusuf, U.; Cunningham, J. M.; Handgretinger, R. // Bone Marrow Transplantation;Jun2004, Vol. 33 Issue 11, p1151 

    Encephalopathy is a poorly characterized complication of hematopoietic stem cell transplantation (HSCT). No comprehensive report of encephalopathy exists for children, and the literature contains only a few for adults. We analyzed a large cohort of 405 pediatric patients who underwent allogeneic...

  • Impact of HLA matching on outcome of hematopoietic stem cell transplantation in children with inherited diseases: a single-center comparative analysis of genoidentical, haploidentical or unrelated donors. Caillat-Zucman, S.; Le Deist, F.; Haddad, E.; Gannaǵe, M.; Cortivo, L. Dal; Jabado, N.; Hacein-Bey-Abina, S.; Blanche, S.; Casanova, J.-L.; Fischer, A.; Cavazzana-Calvo, M. // Bone Marrow Transplantation;Jun2004, Vol. 33 Issue 11, p1089 

    Hematological inherited diseases can be cured by hematopoietic stem cell transplantation (HSCT) from an human leukocyte antigen (HLA)-identical sibling donor (MSD), but the outcome of unrelated donors (URD) or haploidentical donors (HMD) has been a cause of concern. In all, 94 children affected...

  • Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: ‘what is the best recipe?’. Kassim, A. A.; Chinratanalab, W.; Ferrara, J. L. M.; Mineishi, S. // Bone Marrow Transplantation;Oct2005, Vol. 36 Issue 7, p565 

    Summary:Reduced-intensity stem cell transplantation (RIST) has been shown to be a safe and useful alternative transplant method for patients including elderly and medically unfit patients. RIST conditioning regimens vary widely in the intensity of myeloablation, immunoablation, and antileukemia...

  • Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Gratwohl, A.; Baldomero, H.; Schmid, O.; Horisberger, B.; Bargetzi, M.; Urbano-Ispizua, A. // Bone Marrow Transplantation;Oct2005, Vol. 36 Issue 7, p575 

    Summary:This EBMT activity survey presents the status of hematopoietic stem cell transplantation (HSCT) in Europe 2003 and focuses on changes in stem cell source over the last decade. There were 21 028 first HSCT, 7091 allogeneic (34%), 13 937 autologous (66%) and 4179 additional re- or multiple...

  • Emerging trends in transplantation of inherited metabolic diseases. Prasad, V. K.; Kurtzberg, J. // Bone Marrow Transplantation;Jan2008, Vol. 41 Issue 2, p99 

    Allogeneic hematopoietic stem cell transplantation (HSCT) can prolong life and improve its quality in patients with inherited metabolic diseases. HSCT offers a permanent source of enzyme replacement therapy and also might mediate nonhematopoietic cell regeneration or repair. Unrelated cord blood...

  • Results of an Autologous Noncryopreserved, Unmanipulated Peripheral Blood Hematopoietic Stem Cell Transplant Program: A Single-Institution, 10-Year Experience. Ruiz-Argüelles, Guillermo J.; Gómez-Rangel, David; Ruiz-Delgado, Guillermo J.; Ruiz-Argüelles, Alejandro; Pérez-Romano, Beatriz; Rivadeneyra, Liliana // Acta Haematologica;Dec2003, Vol. 110 Issue 4, p179 

    Background: Methods to simplify the stem cell transplantation procedures are needed mainly in developing countries. We have previously shown that unprocessed leukapheresis material is useful to restore hematopoiesis after high-dose chemotherapy. Methods: Over a 10-year period in a private...

  • Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. Imahashi, N; Suzuki, R; Fukuda, T; Kakihana, K; Kanamori, H; Eto, T; Mori, T; Kobayashi, N; Iwato, K; Sakura, T; Ikegame, K; Kurokawa, M; Kondo, T; Iida, H; Sakamaki, H; Tanaka, J; Kawa, K; Morishima, Y; Atsuta, Y; Miyamura, K // Bone Marrow Transplantation;Jan2013, Vol. 48 Issue 1, p56 

    Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with...

  • Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Fagius, J.; Lundgren, J.; Öberg, G. // Multiple Sclerosis (13524585);Feb2009, Vol. 15 Issue 2, p229 

    Background During the last 15 years, high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) has globally been performed for severe multiple sclerosis (MS). Most patients have been in progressive phase with long disease duration. As a rule, treatment effect has been...

  • Patient housing barriers to hematopoietic cell transplantation: results from a mixed-methods study of transplant center social workers. Preussler, Jaime; Mau, Lih-Wen; Majhail, Navneet; Bevans, Margaret; Clancy, Emilie; Messner, Carolyn; Parran, Leslie; Pederson, Kate; Ferguson, Stacy; Walters, Kent; Murphy, Elizabeth; Denzen, Ellen; Preussler, Jaime M; Majhail, Navneet S; Pederson, Kate A; Ferguson, Stacy Stickney; Murphy, Elizabeth A; Denzen, Ellen M // Supportive Care in Cancer;Mar2016, Vol. 24 Issue 3, p1167 

    Purpose: Hematopoietic cell transplantation (HCT) is performed in select centers in the United States (U.S.), and patients are often required to temporarily relocate to receive care. The purpose of this study was to identify housing barriers impacting access to HCT and potential...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics